Insider Trends: Esperion Therapeutics Insider Buy Scaling Back 90-Days of Sells
03:25 PM EDT, 05/07/2021 (MT Newswires) -- Target Biotech Nv, 10% Owner, made a purchase of 230,000 shares in Esperion Therapeutics (ESPR) for $4,648,482 on May 05, 2021. Following the Form 4 filing with the SEC, Target Biotech has 4,177,964 shares of the company, which have a market value of $86.9 million as of the prior-day closing price.
This is the only insider transaction for the company in the last 90 days. In the preceding 90-day window of time, there were 4 transactions from 4 insiders and resulted in the net acquisition of 52,700 shares.
This level of insider transactions is lower than the peer group average in the 207-company Biotechnology & Medical Research peer group over the last 90-day period. Activity in the peer group averaged 65.9 transactions per company, with company insiders acquiring on average 45,187 shares.
SEC Story Link http://www.sec.gov/Archives/edgar/data/1434868/000089924321018635/xslF345X03/doc4.xml
This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.